Meeting
2018 Genitourinary Cancers Symposium
Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).
Authors
Martin Henner Voss
Memorial Sloan Kettering Cancer Center, New York, NY
Martin Henner Voss , Yuan Cheng , Mahtab Marker , Fengshen Kuo , Toni K. Choueiri , James J Hsieh , Albert Reising , Robert J. Motzer , A. Ari Hakimi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT00720941
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 639)
DOI
10.1200/JCO.2018.36.6_suppl.639
Abstract #
639
Poster Bd #
H10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.
First Author: Kelly N. Fitzgerald
Poster
2023 ASCO Genitourinary Cancers Symposium
Dynamic and immunocytochemistry analysis of circulation tumor cells (CTCs) in blood samples from patients with advanced ccRCC starting first-line treatment in a Brazilian Cancer Center.
First Author: Milena Shizue Tariki
Poster
2020 Genitourinary Cancers Symposium
Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.
First Author: Arielle G. Bensimon
Poster
2018 ASCO Annual Meeting
Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
First Author: Dominick Bossé